Paradigm BiopharmaceuticalsPBIGF 18 Operating Margin % is -85,594.12% as of Dec. 2025. GuruFocus rates PBIGF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Paradigm Biopharmaceuticals ranks worse than 97.88% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Paradigm Biopharmaceuticals Operating Margin % Related Terms
Paradigm Biopharmaceuticals Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBIGF vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Paradigm Biopharmaceuticals's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Margin % of -85,594.12% mean?
Paradigm Biopharmaceuticals (PBIGF) has a Operating Margin % of -85,594.12% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #924 out of 944 companies in the Biotechnology industry, placing it in the top 97.9%.
Is Paradigm Biopharmaceuticals' Operating Margin % too high?
Paradigm Biopharmaceuticals' current Operating Margin % is -85,594.12%. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #924 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #924 out of 944 companies for Operating Margin %. This places Paradigm Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Operating Margin % is -85,594.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (PBIGF) has a current Operating Margin % of -85,594.12%. The current Operating Margin % is -85,594.12%. Paradigm Biopharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (PBIGF), the current Operating Margin % is -85,594.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
18GF Score
Get the complete analysis for PBIGF
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBIGF has been successfully added to your 
